The IL-33/ST2 pathway: therapeutic target and novel biomarker
By R. Kakkar, Richard T. Lee. Nature reviews. Drug discovery, 2008
788 citations recorded by the source corpus.
For many years, the interleukin-1 receptor family member ST2 was an orphan receptor that was studied in the context of inflammatory and autoimmune disease. However, in 2005, a new cytokine — interleukin-33 (IL-33) — was identified as a functional ligand for ST2. IL-33/ST2 signalling is involved in T-cell mediated immune responses, but more recently, an unanticipated role in cardiovascular disease has been demonstrated. IL-33/ST2 not only represents a promising cardiovascular biomarker but also a novel mechanism of intramyocardial fibroblast–cardiomyocyte communication that may prove to be a therapeutic target for the prevention of heart failure.
Subfields: Immunology, Surgery
View Paper: https://www.semanticscholar.org/paper/fac42f223a75d485682702c900bb4001dbd5d270
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Surgery
Citations in the corpus
- The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1 (2009, background): “Based on animal model studies and analyses of diseased tissues from patients, IL-33 has been proposed to represent a promising therapeutic target for several important diseases, including asthma and other allergic diseases (4), rheumatoid arthritis (5, 6), atherosclerosis (7), and cardiovascular dis”
- Dilated Cardiomyopathy (2007, background): “Another biomarker of inflammation and fibrosis is sST2, a member of the interleukin (IL)-1 receptor-like family, that is secreted in response to myocardial strain and IL1 stimulation [46].”